Table 1: Baseline and treatment response factors predictive of sustained remission in the double-blind phase in the active treatment groups.

Predictor Quartiles of Response, n/N (%) p-value*
Reduced-Dose Combination Therapy
First DAS28 remission, day 13–57 58–179 180–273 ≥274
n/N (%) 12/15 (80) 16/20 (80) 8/16 (50) 4/12 (33) <0.01
First DAS28 LDA, day 1–29 30–57 58–183 ≥184
n/N (%) 12/14 (86) 12/20 (60) 10/15 (67) 6/14 (43) <0.05
Mean DAS28, week 52 ≤1.55 >1.55−1.91 >1.91−2.16 >2.16
n/N (%) 14/16 (88) 11/16 (69) 7/15 (47) 8/16 (50) <0.05
Methotrexate Monotherapy
Age, BL, years 19–39 40–48 49–60 ≥61
n/N (%) 11/15 (73) 8/22 (36) 2/15 (13) 5/13 (38) <0.05
CRP level, week 52, mg/L 0–0.50 >0.50–1.09 >1.09–2.91 >2.91
n/N (%) 9/16 (56) 8/14 (57) 6/18 (33) 2/16 (13) <0.01

* Mantel–Haenszel chi-square correlation (trend) test (univariate).
BL: baseline; CRP: C-Reactive Protein; DAS28: Disease Activity Score for 28-joint counts; LDA: Low Disease Activity.

Back to Article